Prostatype Genomics Study Shows Prostatype Outperformed NCCN Benchmark
Prostatype Genomics reported 20-year study data from 137 patients indicating that Prostatype outperformed the NCCN benchmark. The study also showed no low-risk patients classified by Prostatype died of prostate cancer. The data are currently under Medicare review for US reimbursement.